This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Sharon Safrin, MD; Valerie L. Ng, PhD, MD; Michael S. McGrath, MD, PhD; Bonnie J. Dattel, MD; Laurie Hauer, RN; Richard L. Sweet, MD
University of California, San Francisco

JAMA. 1990;263(16):2181.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We studied the seroprevalence of human T-cell lymphotropic virus type I/II (HTLV-I/II) antibody in 333 women admitted to San Francisco General Hospital with acute pelvic inflammatory disease between January 1985 and December 1988. Testing was limited to banked serum samples from women who had enrolled in antibiotic research studies, representing 45% of women admitted with acute pelvic inflammatory disease during this period. Antibody to chromatographically purified (C91/PL) HTLV-I was detected by immunoblot; reactivity with p24 and p19 was confirmed by two separate observers.

Seroprevalence of HTLV-I/II was 3.0% (95% confidence interval, 1.2% through 4.8%). There was no evidence of increasing prevalence of infection during the 4-year time span: 2 (12.5%) of 16 patients in 1985, 4 (3.9%) of 103 in 1986,4 (4.2%) of 95 in 1987, and 0 (0%) of 119 in 1988. In this same sample, seroprevalence of human immunodeficiency virus type 1 was 4.2% (95% . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?